Julia Dudnik

478 total citations
23 papers, 143 citations indexed

About

Julia Dudnik is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Julia Dudnik has authored 23 papers receiving a total of 143 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Julia Dudnik's work include Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Julia Dudnik is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Julia Dudnik collaborates with scholars based in Israel, United States and Japan. Julia Dudnik's co-authors include Samuel Ariad, Hovav Nechushtan, Nir Peled, Waleed Kian, Laila C. Roisman, Jair Bar, Ilan Shelef, Netta Sion‐Vardy, Guy Shalom and Lorenzo Livi and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

Julia Dudnik

20 papers receiving 143 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julia Dudnik Israel 9 89 86 32 17 16 23 143
Carl Cook United States 8 41 0.5× 93 1.1× 59 1.8× 24 1.4× 11 0.7× 12 137
Serena Corsetti Italy 8 34 0.4× 55 0.6× 28 0.9× 15 0.9× 25 1.6× 19 112
Yujia Chi China 11 125 1.4× 110 1.3× 41 1.3× 21 1.2× 21 1.3× 20 209
Nicholas Venturini United States 5 53 0.6× 87 1.0× 42 1.3× 78 4.6× 21 1.3× 9 164
Yu Yu China 5 60 0.7× 139 1.6× 32 1.0× 53 3.1× 31 1.9× 6 197
Wei‐Sen Lam Australia 7 143 1.6× 107 1.2× 27 0.8× 13 0.8× 6 0.4× 15 230
Margaux Geier France 8 150 1.7× 167 1.9× 23 0.7× 18 1.1× 17 1.1× 41 220
Sara Manglaviti Italy 7 59 0.7× 72 0.8× 28 0.9× 8 0.5× 28 1.8× 23 136
Ashraf Azzabi United Kingdom 5 140 1.6× 62 0.7× 27 0.8× 4 0.2× 11 0.7× 13 208
David Queiroz Borges Muniz Brazil 6 53 0.6× 59 0.7× 30 0.9× 8 0.5× 14 0.9× 17 119

Countries citing papers authored by Julia Dudnik

Since Specialization
Citations

This map shows the geographic impact of Julia Dudnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Dudnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Dudnik more than expected).

Fields of papers citing papers by Julia Dudnik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia Dudnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Dudnik. The network helps show where Julia Dudnik may publish in the future.

Co-authorship network of co-authors of Julia Dudnik

This figure shows the co-authorship network connecting the top 25 collaborators of Julia Dudnik. A scholar is included among the top collaborators of Julia Dudnik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia Dudnik. Julia Dudnik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Herbst, Roy S., Byoung Chul Cho, Mauricio Burotto, et al.. (2025). Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study. Journal of Thoracic Oncology. 20(9). 1302–1314.
2.
3.
Herbst, Roy S., Byoung Chul Cho, Caicun Zhou, et al.. (2023). 64O Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy for metastatic non squamous non-small cell lung cancer (NSCLC): Phase III LEAP-006 study. Immuno-Oncology Technology. 20. 100536–100536. 3 indexed citations
4.
Yang, James Chih‐Hsin, Baohui Han, Emmanuel de la Mora Jimenez, et al.. (2023). Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. Journal of Thoracic Oncology. 19(6). 941–953. 21 indexed citations
5.
6.
Yang, James Chih‐Hsin, Alexander Luft, Emmanuel de la Mora Jimenez, et al.. (2021). 120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study. Annals of Oncology. 32. S1429–S1430. 18 indexed citations
7.
Kian, Waleed, Laila C. Roisman, Julia Dudnik, et al.. (2021). 1173P Induction osimertinib in EGFR-mutant stage IIIA/B NSCLC. Annals of Oncology. 32. S941–S941.
8.
Zer, Alona, Julia Dudnik, Sivan Shamai, et al.. (2021). 1331P Open-label phase I/II study evaluating the tolerability and anti-tumor activity of selinexor (SEL) and docetaxel (DTX) in non-small cell lung cancer (NSCLC). Annals of Oncology. 32. S1019–S1019. 1 indexed citations
9.
Roisman, Laila C., Waleed Kian, Julia Dudnik, et al.. (2021). The impact of osimertinib’ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance. Lung Cancer. 153. 126–133. 16 indexed citations
10.
Dudnik, Elizabeth, Jair Bar, Assaf Moore, et al.. (2021). BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors. Frontiers in Oncology. 11. 603223–603223. 14 indexed citations
11.
Rennert, Gad, Maya Gottfried, Hedy S. Rennert, et al.. (2020). Long term follow-up of EGFR mutated NSCLC cases. Translational Oncology. 14(1). 100934–100934. 8 indexed citations
12.
Bar, Jair, Marina Perelman, Damien Urban, et al.. (2020). Rising Incidence of Lung Cancer in Arab Females, Jewish Females, and Arab Males from 1990 to 2014 in Israel.. PubMed. 22(12). 788–793. 2 indexed citations
13.
Roisman, Laila C., Julia Dudnik, Hovav Nechushtan, et al.. (2020). Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. Neuro-Oncology Advances. 2(1). vdaa125–vdaa125. 12 indexed citations
14.
Dudnik, Elizabeth, Jair Bar, Mor Moskovitz, et al.. (2019). P2.06-14 BAP1 Mutant Malignant Pleural Mesothelioma (MPM): Outcomes with Chemotherapy, ICPi and PARPi. Journal of Thoracic Oncology. 14(10). S760–S760. 1 indexed citations
15.
Hod, Nir, et al.. (2019). 68Ga-DOTATATE PET/CT in Focal Fatty Sparing of the Liver. Clinical Nuclear Medicine. 44(10). 815–817. 3 indexed citations
16.
17.
18.
Bar, Jair, Arnold Cyjon, Dov Flex, et al.. (2014). EGFR Mutation Testing Practice in Advanced Non-Small Cell Lung Cancer. Lung. 192(5). 759–763. 5 indexed citations
19.
Shalom, Guy, Netta Sion‐Vardy, Julia Dudnik, & Samuel Ariad. (2010). Leukemoid reaction in lung cancer patients.. PubMed. 12(4). 255–6. 12 indexed citations
20.
Mermershtain, Wilmosh, et al.. (2001). Acute Myocardial Infarction in a Young Man Receiving Chemotherapy for Testicular Cancer: Case Report. Journal of Chemotherapy. 13(6). 658–660. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carl Cook Breakdown of academic impact, for papers by Serena Corsetti Breakdown of academic impact, for papers by Yujia Chi Breakdown of academic impact, for papers by Nicholas Venturini Breakdown of academic impact, for papers by Yu Yu Breakdown of academic impact, for papers by Wei‐Sen Lam Breakdown of academic impact, for papers by Margaux Geier Breakdown of academic impact, for papers by Sara Manglaviti Breakdown of academic impact, for papers by Ashraf Azzabi Breakdown of academic impact, for papers by David Queiroz Borges Muniz
Rankless by CCL
2026